NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

First Tracks Biotherapeutics, Inc. (TRAX) Stock Analysis

First Tracks Biotherapeutics, Inc. (TRAX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

TRAX

$40.46

−$2.05 (−4.82%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TRAX with… →

TRAX Key Statistics

As of Sep 4, 2026
Trading
Open
$41.06
Previous Close
$42.51
Day's Range
40.38–42.00
52-Week Range
14.72–49.91
Volume
456.20K
Valuation
Market Cap
$1.45B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.48
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$163.71M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
35.73M
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
773.16K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TRAX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2024$0.00−$163.71M—
2023$0.00−$106.15M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2024$0.00—−$181.10M−$163.71M—
2023$0.00—−$118.46M−$106.15M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2024.

TRAX Valuation vs Biotechnology Median

Median of 656 stocks
MetricTRAXBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

First Tracks Biotherapeutics, Inc. (TRAX) is capitalised at $1.45B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 104.

The 52-week range on file runs from $14.72 to $49.91. TRAX last closed at $40.46 on September 4, 2026. That is −$2.05 (−4.82%) against the previous close. The latest close sits 174.86% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2024, shows revenue of $0.00. The same year closed with a net loss of $163.71M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −4.48.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Growth & Income

The record shows no dividend for TRAX.

So far in 2026 the price is +112.95%.

Peer Comparison

First Tracks Biotherapeutics, Inc. (TRAX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
First Tracks Biotherapeutics, Inc. TRAX $1.45B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. First Tracks Biotherapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About First Tracks Biotherapeutics, Inc.

First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.

Visit website →